 The FDA crushed MEI Pharma Incs NASDAQ: MEIP hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the meeting, the FDA informed that a randomized clinical trial is needed to adequately assess drug efficacy and safety. 